| Author (year) |
Patients (n) |
PLA2R1+(n,%) |
Assay |
Remarks |
| Beck et al. (2009) [6] |
37 |
26,7 |
WB |
|
| Hofstra et al. [8] |
18 |
14,78 |
WB |
|
| Beck et al. (2011) [25] |
35 |
25,71 |
WB |
|
| Debiec and Ronco [7] |
42 |
24,57 |
IF |
|
| Hoxha et al. [20] |
100 |
52,52 |
IF |
|
| Qin et al. [18] |
60 |
49,82 |
WB |
Cross-sectional study; 66% positive if limiting analysis to patients with proteinuria >3.5 g/day |
| Hoxha et al. [20] |
24 |
14,58 |
WB |
Low titres of PLA2R present in 10/11 patients who were negative in standard assay Renal biopsies with mesangial or subendothelial deposits or glomerular infiltrating cells were excluded |
| Beck et al. (2011) [25] |
14 |
12,86 |
WB |
Patient characteristics not provided |
| Hoxha et al. [20] |
81 |
53,65 |
IF |
Prospective study |
| Schönermarck [9] |
16 |
11,69 |
IF |
|
| Kanigicherla et al. [19] |
40 |
29,73 |
ELISA |
|
| Hofstra et al. [8] |
117 |
86,74 |
IF/ELISA |
Cross-sectional study; table reflects only patients with active disease |
| Hofstra et al. [8] |
88 |
61,69 |
IF/IF |
Authors develop a standardized ELISA for the determination of autoantibodies against PLA2R1 that can be made widely available and used in a routine setting for clinical applications. |
| Salant [10] |
200 |
196,98 |
ELISA |
Prospective study |
| Oh et al. [26] |
100 |
69,69 |
WB |
Authors develop a standardized ELISA |
| Behnert et al. [24] |
165 |
85,52 |
IF/WB/ALBIA |
Authors explored the relationship between anti-PLA2R and disease activity and clinical outcomes.
An Anti-Phospholipase A2 Receptor Quantitative Immunoassay |
aPLA2R +: anti-PLA2R antibodies detectable; WB: Western blot; IF: immunofluorescence test; ELISA: Enzyme-linked Immunosorbent Assay; ALBIA: Addressable Laser
Bead Immunoassay |
